Does Rallies show 13F holders for PVLA?

Yes. Rallies tracks hedge fund and 13F ownership data for PVLA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PVLA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PVLA. It does not provide personalized investment advice.

PVLA (Palvella Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Palvella Therapeutics, Inc. Common Stock (PVLA) is a publicly traded Healthcare sector company. As of May 21, 2026, PVLA trades at $115.50 with a market cap of $1.51B and a P/E ratio of -30.54. PVLA moved +5.56% today. Year to date, PVLA is +30.60%; over the trailing twelve months it is +397.20%. Its 52-week range spans $11.17 to $151.18. Analyst consensus is strong buy with an average price target of $231.00. Rallies surfaces PVLA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PVLA stock?

Hedge funds tracked by Rallies that own PVLA include Orbimed Advisors, Bluecrest Capital, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Palvella Therapeutics, Inc. Common Stock.

PVLA Key Metrics

Key financial metrics for PVLA
Metric	Value
Price	$115.50
Market Cap	$1.51B
P/E Ratio	-30.54
EPS	$-3.71
Dividend Yield	0.00%
52-Week High	$151.18
52-Week Low	$11.17
Volume	0
Avg Volume	0
Revenue (TTM)	$2.59M
Net Income	$-41.72M
Gross Margin	0.00%

Top Hedge Funds Holding PVLA

Orbimed Advisors holds 134.60K shares of PVLA, changed +0.00% as of Mar 31, 2026.
Bluecrest Capital holds 20.00K shares of PVLA, changed +0.00% as of Mar 31, 2026.
Mangrove Partners holds 1.79K shares of PVLA, changed +0.00% as of Mar 31, 2026.

Latest PVLA News

Palvella’s QTORIN Rapamycin Delivers +2.5-Point Bleeding Score Gain in Phase 2 Trial — May 15, 2026
Palvella Therapeutics Uplists to Nasdaq Global Market After Meeting Higher Listing Standards — May 13, 2026
Palvella Raises $230M, Secures FDA Pre-NDA Meeting for QTORIN Q2 — May 7, 2026
Palvella to present significant Phase 3 SELVA and Phase 2 TOIVA rapamycin data on May 20 — Apr 20, 2026
Palvella Names John D. Doux to Board to Advance QTORIN™ Rare Disease Pipeline — Apr 13, 2026

Recent PVLA Insider Trades

Goin Kathleen sold 1.50K (~$189.20K) on Apr 15, 2026.
Goin Kathleen sold 1.50K (~$190.69K) on Apr 15, 2026.
Goin Kathleen sold 561 (~$71.94K) on Apr 15, 2026.

PVLA Analyst Consensus

14 analysts cover PVLA: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $231.00.

Common questions about PVLA

Who owns PVLA stock?: Hedge funds tracked by Rallies that own PVLA include Orbimed Advisors, Bluecrest Capital, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Palvella Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for PVLA?: Yes. Rallies tracks hedge fund and 13F ownership data for PVLA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PVLA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PVLA. It does not provide personalized investment advice.